(Prostate Cancer) Custirsen Plus Cabazitaxel: ESMO 2016 AFFINITY Phase 3 Trial Results
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- October 26, 2016
- 1 min read
At ASCO 2010, J.S. De Bono of Royal Marsden NHS Foundation Trust published results demonstrating that cabazitaxel was effective in prostate cancer patients previously treated with docetaxel. This month at ESMO 2016, Karim Fizazi of Institut Gustave Roussy (France) presented Phase 3 clinical trial results for custirsen.
Custirsen (OGX-011) is a second-generation antisense oligonucleotide that blocks the anti-apoptotic mechanisms in cancer cells. Phase 2 clinical trial results comparing docetaxel alone versus docetaxel plus custirsen showed no significant difference in OS; however, subgroup analysis revealed better recovery outcomes with the combination. Based on this finding, a Phase 3 trial was initiated.
AFFINITY Phase 3 Trial Design:
A total of 635 subjects were enrolled. Eligibility required prior docetaxel treatment for castration-resistant prostate cancer. Patients were randomized to custirsen + cabazitaxel/prednisone versus cabazitaxel/prednisone alone.
- Custirsen arm: Cabazitaxel 25 mg/m² every 21 days + prednisone 10 mg daily + custirsen 640 mg (3 loading doses followed by weekly maintenance)
- Up to 10 treatment cycles in the absence of severe adverse events
Primary endpoints: overall OS and OS in poor-prognosis patients.
Poor-prognosis definition (2 of 5 criteria): Karnofsky PS ≤80%, liver metastases, Hb <12 g/dL, LDH ≥360 IU/L, PSA ≥150 ng/mL. Poor-prognosis patients: custirsen arm 61.5%, control arm 61.9%.
Results:
- Median OS (all patients): Custirsen arm 14.2 months vs. control arm 13.4 months
- No significant difference between arms
Safety:
No particular safety concerns. Grade 3+ adverse events: custirsen arm 76% vs. control arm 66%. Common adverse events included anemia, leukopenia, diarrhea, and back pain.
Conclusion: In previously docetaxel-treated, castration-resistant prostate cancer patients, the addition of custirsen to cabazitaxel did not provide additional therapeutic benefit.
Prostate Cancer | Custirsen | Cabazitaxel | ESMO 2016
-
Clinical Trial Medications
- (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
- (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
- (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4